

**EC/MDD DECLARATION OF CONFORMITY**

This is a declaration made in accordance with the requirements of Council Directive 93/42/EEC of 14 June 1993 concerning medical devices (MDD 93/42/EEC).



**Manufacturer's Name:** NIHON KOHDEN CORPORATION  
**Business Address:** 1-31-4 Nishiochiai, Shinjuku-ku  
Tokyo 161-8560, Japan

**European Representative:** NIHON KOHDEN EUROPE GmbH  
**Address:** Raiffeisenstrasse 10, D - 61191 Rosbach, Germany

**Product Name and Model Name:**

SpO2 Probe	TL-271T
SpO2 Probe	TL-272T
SpO2 Probe	TL-273T
SpO2 Probe	TL-274T
SpO2 Probe	TL-271T3
SpO2 Probe	TL-272T3
SpO2 Probe	TL-273T3
SpO2 Probe	TL-274T3

**Classification:** IIa

Each kind of medical device to which the Full Quality Assurance Procedures (Annex II) have been applied complies with the applicable provisions of the essential requirements, the classification rules, at each stage, from the design of the device until its final inspection before being supplied.

**Notified Body:** BSI Group The Netherlands B.V.  
**EC Certificate:** CE 01342

**Standard Applied:**

- EN ISO 13485: 2016
- EN ISO 14971: 2012
- ISO 10993-1: 2009
- ISO 80601-2-61: 2017
- IEC 60601-1: 2005
- IEC 60601-1 Amendment 1: 2012
- IEC 60601-1-6: 2010
- IEC 60601-1-6 Amendment 1: 2013
- IEC 62366: 2007
- IEC 62366 Amendment 1: 2014
- EN 1041: 2008
- EN 1041 Amendment 1: 2013
- EN ISO 15223-1: 2016

**Note:**

The underlined standard above is updated in this Declaration of Conformity.

Although the Declaration is issued after 26 May 2021, the Date of Application of MDR, the Declaration is made for the changes which do not correspond to significant changes specified in the MDCG 2020-3, and maintains compliance with the old standards listed on the Declaration dated 15 March 2019.

Consequently, this Declaration does not deviate from the MDR Article 120, and does not invalidate the Declaration of 15 March 2019.

**Authorized Signatory:**Tokyo, Japan / 18 February 2022

Place and date of issue

  
\_\_\_\_\_  
Hiroko Hagiwara  
General Manager  
Clinical Development & Regulatory Affairs Division